Synthetic Biologics' C. difficile drug, ribaxamase, achieved its primary endpoint in a phase 2b trial.
Researchers tested the drug in a randomized, double-blind placebo controlled study of 412 patients.
Here's what you should know.
1. The drug significantly reduces C. difficile infection.
2. Of the patients, there were seven confirmed infections in the placebo group and two in the ribaxamase group.
3. Patients receiving ribaxamase achieved a 71.4 percent relative risk reduction in CDI rates compared to patients receiving a placebo.
4. Adverse events reported were comparable between both groups.